Clinical Trials Browser

Phase 3 × alectinib × Clear all

NCT02838420 2026-03-18

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Active not recruiting

187 enrolled 14 charts

Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

NCT05170204 2026-03-06

HORIZON 1

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03194893 2026-02-20

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Phase 3 Active not recruiting

EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Multiple Endocrine Neoplasia Type 2a

NCT06765109 2026-02-17

ALKAZAR

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT06624059 2026-01-21

HORIZON 2

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03596866 2025-09-12

ALTA-3

Phase 3 Completed

248 enrolled 20 charts

ALK+ Advanced NSCLC

NCT02075840 2025-07-25

ALEX

Phase 3 Completed

303 enrolled 31 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02604342 2019-10-29

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Phase 3 Completed

119 enrolled 33 charts

Carcinoma, Non-Small-Cell Lung